Skip to main content Accessibility help

Assessment of Suspected Dementia

  • H. Chertkow (a1) (a2) (a3) (a4), H. Bergman (a1) (a2), H.M. Schipper (a1) (a2), A.M. Clarfield (a5), S. Gauthier (a4), S. Fontaine (a6) and R. Bouchard (a7)...


At the Second Canadian Consensus Conference on Dementia (CCCD) (February, 1998), a group of neurologists, geriatricians, and psychiatrists met to consider guidelines for evaluation of dementia in Canada. This review paper formed a background paper for their discussion of dementia diagnosis. These experts from across the country concluded that diagnosis of suspected dementia cases continued to rest on skilled clinical assessment. Mental status exam, preferably in some quantifiable form, has become an essential part of the assessment. Selected laboratory tests are advisable in all cases (CBC, TSH, electrolytes, calcium, and glucose), but the CCCD continued to advise that CT scanning was mandatory only in selected cases where clinical findings pointed to another possibility besides Alzheimer’s disease. The growing list of other diagnostic measures with potential usefulness in diagnosis of Alzheimer’s disease or dementia in general was reviewed, but the evidence was judged as insufficient to support routine use of these tests by physicians. As new treatments for Alzheimer’s disease become available, neurologists face new diagnostic challenges - differentiating Mild Cognitive Impairment, Frontotemporal dementias and Mixed dementias, and Lewy Body Dementia. Guidelines to aid in differential diagnosis are presented.

    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Assessment of Suspected Dementia
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Assessment of Suspected Dementia
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Assessment of Suspected Dementia
      Available formats



Hide All
1. Reisberg, B, Ferris, S. Diagnosis and assessment of the older patient Hosp Community Psychiatry 1982; 33 (2): 104110.
2. Blackford, RC, LaRue, A. Criteria for diagnosing age-associated memory impairment: proposed revisions from the field Dev Neuropsychol 1989; 5: 295306.
3. Dawe, B, Procter, A. Concepts of mild memory impairment in the elderly and their relationship to dementia — a review Int J Geriatr Psychiatry 1992; 7: 473479.
4. Salthouse, TA. Adult Cognition: An Experimental Psychology of Human Aging. New York: Springer Verlag, 1982.
5. Garcia, C, Reding, M, Blass, J. Overdiagnosis of dementia J Am Geriatr Soc 1981; 29: 407410.
6. Ebly, EM, Hogan, DB, Parhad, IM. Cognitive impairment in the nondemented elderly Results from the Canadian Study of Health and Aging. Arch Neurol 1995; 52 (6): 612619.
7. Kral, VA. Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962; 86: 257260.
8. Crook, T, Bartus, RT, Ferris, SH, et al. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change: Report of a National Institute of Mental Helath Work Group Dev Neuropsychol 1986; 2: 261276.
9. Hughes, C, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566572.
10. Berg, L. Clinical dementia rating (CDR). Psychopharmacol Bull 1988; 24 (4): 637639.
11. Levy, R. Report of the working party of the International Psychogeriatric Association in collaboration with the World Health Organization: aging–associated cognitive decline [published erratum appears in Int Psychogeriatr 1994;6(2):133]. Int Psychogeriatr, 1994; 6 (1): 6368.
12. Petersen, RC, Smith, GE, Tangalos, EG, Kokmen, E, Ivnik, RJ. Longitudinal outcome of patients with a mild cognitive impairment Ann Neurol 1993; 34: 294295.
13. Ritchie, K, et al. A typology of sub-clinical senescent cognitive disorder. Br J Psychiatry 1996; 168 (4): 470476.
14. Zaudig, M. Anew systematic method of measurement and diagnosis of mild cognitive impairment and dementia according to ICD-10 and DSM-III-R criteria. Int Psychogeriatr 1992; 4 (Suppl.2): 203219.
15. Petersen, RC, et al. Mild cognitive impairment: clinical characterization and outcome [published erratum appears in Arch Neurol 1999;56(6):760]. Arch Neurol 1999; 56 (3): 303308.
16. Daly, E, et al. Predicting conversion to Alzheimer’s disease using standardized clinical information. Arch Neurol 2000; 57 (5): 675680.
17. O’Connor, DW. Mild dementia: a clinical perspective. In: Hippert FA, Brayne C, O’Connor DW, eds. Dementia and Normal Aging. Cambridge University Press Cambridge. 1994; 91118.
18. Chertkow, H. Mild memory loss in the elderly: can we predict development in dementia? Can J Neurol Sci 1998; 25 (1): S1–S4.
19. Hanninen, T, et al. A follow-up study of age-associated memory impairment: neuropsychological predictors of dementia. JAGS 1995; 43 (9): 10071015.
19a. Hogan, DB, Ebly, EM. Predicting who will develop dementia in a cohort of Canadian seniors. Can J Neurol Sci 2000; 27: 1824.
20. Morris, J. Healthy brain aging in nonagenarians and centenarians. Neurobiol Aging 2000; 21 (1S): S280.
21. Ritchie, K, Touchon, J. Mild cognitive impairment: conceptual basis and current nosological status [see comments]. Lancet 2000; 355 (9199): 225258.
22. Morris, JC, et al. Very mild Alzheimer’s disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 1991; 41 (4): 469478.
23. Tierney, MC, et al. The prediction of Alzheimer’s disease. The role of patient and informant perceptions of cognitive deficits. Arch Neurol 1996; 53 (5): 423427.
24. McGlone, J, et al. Screening for early dementia using memory complaints from patients and relatives. Arch Neurol 1990; 47 (11): 11891193.
25. Jorm, A, et al. Do cognitive complaints either predict future cognitive decline or reflect past cognitive decline? A longitudinal study of an elderly community sample. Psychol Med 1997; 27 (1): 9198.
26. Schofield, PW, et al. The validity of new memory complaints in the elderly. Arch Neurol 1997; 54 (6): 756759.
27. Chertkow, HM, et al. Standard neuropsychological tests do not predict development of Alzheimer’s disease in indivduals with “Age-associated Cognitive Decline”. Can J Neurol Sci 1998; 25 (Suppl2): S27 (Abstract).
28. Fellows, L, Chertkow, H Bergman, H. Can clinical data predict progression to Alzheimer’s disease in patients with mild memory impairment?. Can J Neurol Sci 1998; 25 (Suppl2): S28 (Abstract).
29. Verret, L, et al. Disorientation to time as a predictor of progression to Alzheimer’s disease for age-associated cognitive decline patients. Can J Neurol Sci 1999; 26 (Suppl1): S16.
30. (CSHA). Canadian Study of Health and Aging: Risk factors for Alzheimer’s disease in Canada. Neurology 1994; 44 20732080.
31. Graham, JE, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997; 349 (9068): 17931796.
32. (APA). A PA, Diagnostic and Statistical Manual of Mental Disorders, 4th ed.: DSM-IV. 4th ed. Washington, DC. 1994.
33. Gélinas, I. Disability assessment in dementia of the Alzheimer’s type. In: School of Physical and Occupational Therapy. McGill University: Montreal. 1995.
34. Gauthier, L. Gelinas I. Development of a functional measure for persons with Alzhaeimer’s disease: the disability assessment for dementia. Am J Occup Ther 1999; 53 471481.
35. Reisberg, B. Functional assessment staging (FAST). Psychopharmacol Bull 1988; 24 653659.
36. Rosenman, S. The validity of the diagnosis of mild dementia. Psychol Med 1991; 21 (4):923934.
37. Erkinjuntti, T, The effect of different diagnostic criteria on the prevalence of dementia. New Eng J Med 1997; 337 (23):16671674.
38. Wells, C. Chronic brain disease: an overview. Am J Psychiatry 1998; 135 112.
39. Clarfield, AM. The reversible dementias: do they reverse? Ann Int Med 1988; 109 (6):476486.
40. Clarfield, AM, Foley, JM. The American and Canadian consensus conferences on dementia: is there consensus? [see comments]. J Am Geriatr Soc 1993; 41 (8):883886.
41. Skoog, I, et al. A population-based study of dementia in 85-yearolds [see comments]. New Eng J Med 1993; 328 (3):153158.
42. Evans, DA, Funkenstein, H, Albert, MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons. JAMA 1989; 262 (18):25512556.
43. Weytingh, MD, Bossuyt, PM, van Crevel, H. Reversible dementia: more than 10% or less than 1%? A quantitative review. J Neurology 1995; 242: 466471.
44. Walstra, GJ, Teunisse, S, van Gool, W van Crevel, H. Reversible dementia in elderly patients referred to a memory clinic. J Neurology 1997; 244: 1722.
45. Geldmacher, D, Whitehouse, P. Evaluation of dementia. New Eng J Med 1996; 335 (5): 330336.
46. Geldmacher, DS, Whitehouse, PJ Jr. Differential diagnosis of Alzheimer’s disease. Neurology 1997; 48 (5 Suppl6): S2–S9.
47. Kaye, JA Diagnostic challenges in dementia. Neurology 1998; 51 (Suppl1): S45–S52.
48. Royall, DR, Polk, M. Dementias that present with and without posterior cortical features: an important clinical distinction. J Am Geriatr Soc 1998; 46 (1): 98105.
49. (CSHA) C.S.o.H.a.A. Canadian Study of Health and Aging Working Group: study methods and prevalence of dementia. Can Med Assoc J 1994; 150: 899913.
50. McKhann, G, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAwork group under the auspices of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34 939944.
51. Black, SE. Focal cortical atrophy syndromes. Brain Cogn 1996 31 (2): 188229.
52. Neary, D, et al. Neuropsychological syndromes in presenile dementia due to cerebral atrophy. J Neurol Neurosurg Psychiatry 1986 49 163174.
53. Neary, D. Non Alzheimer’s disease forms of cerebral atrophy [editorial]. J Neurol Neurosurg Psychiatry 1990 53 (11) 929931.
54. Gibb, WR. et al. Cortical Lewy body dementia: clinical features and classification. J Neurol Neurosurg Psychiatry 1989 52 (2) 185192.
55. Snowdon, J, Griffiths, H, Neary, D. Progressive language disorder associated with frontal lobe degeneration. Neurocase 1996 2 429440.
56. Kertesz, A, Davidson, W, Fox, H. Frontal behavioral inventory:diagnostic criteria for frontal lobe dementia. Can J Neurol Sci 1997 24 (1) 2936.
57. Neary, D, et al Frontotemporal lobal degeneration. A concensus on clinical diagnostic criteria Neurology 1998 51 (6) 15461554.
58. Chow, TW, et al Inheritance of frontotemporal dementia. Arch Neurol 1999 56 (7) 817822.
59. Perry, RJ, Hodges, JR. Differentiating frontal and temporal variant frontotemporal dementia from Alzheimer's disease. Neurology 2000; 54 (12) 22772284.
60. Rahman, S, et al Specific cognitive deficits in mild frontal variant frontotemporal dementia. Brain 1999; 122 (8) 14691493.
61. Miller, BL, et al Frontal lobe degeneration: clinical, neuropsychological, and SPECT characteristics. Neurology 1991; 41 (9) 13741382.
62. Al-Asmi, A, Chertkow, H, Albrecht, S, et al Amyotrophic lateral sclerosis presenting as restricted cognitive impairment. In:American Neuropsychiatric Association meeting Honolulu, USA. 1998;
63. Marsden, CD., Neurological causes of dementia other than Alzheimer’s disease. In: Burrows K, ed. Handbook of Studies on Psychiatry and Old Age Elsevier Science Publishers B.V.. 1984; 145167.
64. Cummings, JL, Victoroff, JI. Noncognitive neuropsychiatric syndromes in Alzheimer’s disease. Neuropsychiatry Neuropsychol Behav Neurol 1990; 3 (2) 140158.
65. Chui, HC, et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992; 42: 473480.
66. Rockwood, K, et al. Diagnosis of vascular dementia: Consortium of Canadian Centres for Clinical Cognitive Research Consensus Statement. Can J Neurol Sci 1994; 21: 358364.
67. Roman, GC, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop Neurology 1993; 43: (2): 250260.
68. Amar, K, et al. The presence of leuko-araiosis in patients with Alzheimer’s disease predicts poor tolerance to tacrine, but does not discriminate responders from non-responders. Age Ageing Neurology 1997; 26: (1): 2529.
69. Gold, M. et al. Physostigmine and Alzheimer's disease [letter; comment]. Neurology 1997; 49: (2): 642643.
70. Corey-Bloom, J, et al. Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia. J Am Geriatr Soc 1993; 41: (1): 3137.
71. Hachinski, VC, Iliff, LD, Zilhka, E et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632637.
72. Rosen, WG, Terry, RD, Fuld, PA, Katzman, R, Peck, A. Pathological verification of ischemic score in differentiation of dementia. Ann Neurol 1980; 7: 486488.
73. Boller, F, Lopez, OL, Moossy, J., Diagnosis of dementia:clinicopathologic correlations. Neurology 1989; 39 (1): 7679.
74. Snowdon, DA, et al. Brain infarction and the clinical expression of Alzheimer’s disease: the nun study. JAMA 1997; 277 (10): 813817.
75. Forette, F, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial [see comments]. Lancet 1998; 352 (9137): 13471351.
76. Mayeux, R, Stern, Y, Spanton, S., Heterogeneity in dementia of the Alzheimer’s type: evidence of subgroups. Neurology 1985; 35 (4): 453461.
77. Mayeux, R, Stern, Y., Spanton, S., Intellectual dysfunction and dementia in Parkinson 's disease. In: Mayeux R, Rosen WG. eds. The Dementias Raven Press: New York.1983; 211227.
78. McKeith, IG, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB):report of the consortium on DLB international workshop. Neurology 1996; 47 (5): 11131124.
79. Gomez-Tortosa, E, et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999; 53 (6): 12841291.
80. Verghese, J, et al. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999; 53 (9): 19741982.
81. McKeith, IG, Perry, EK, Perry, RH., Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Neurology 1999; 53 (5): 902905.
82. Lopez, OL, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999; 53 (6): 12921299.
83. Litvan, I, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47 (1): 19.
84. Pillon, B, et al. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson’s disease, and Alzheimer’s disease. Neurology 1986; 36 (9): 11791185.
85. Johnson, RT, Gibbs, CJ Jr. et al. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. New Eng J Med 1998; 339 (27): 19942004.
86. Kretzschmar, HA, et al. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996; 53 (9): 913920.
87. Zerr, I., et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998; 43 (1): 3240.
88. Schneider, JA, et al. Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 1997; 48 (4): 959969.
89. Kertesz, A, et al. The pathology and nosology of primary progressive aphasia [see comments]. Neurology 1994; 44 (11): 20652072.
90. Grimes, DA, Lang, AE, Bergeron, CB Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999; 53 (9): 19691974.
91. Caine, ED, Neuropsychology of depression: the pseudodementia syndrome. In: Grant I, Adams KM. eds. Neuropsychological Assessment of Neuropsychiatric Disorders Oxford University Press New York, 1986.
92. McAllister, TW, Price TRP. Severe depressive pseudodementia with and without dementia. Am J Psychiatry 1982; 139: 626628.
93. Reifler, B, Larson, E, Hanley, R. Coexistence of dementia and depression in geriatric outpatients. Am J Psychiatry 1982; 139: 623625.
94. Erkinjuntti, T, et al. Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and postmortem neuropathological study. J Neurol Neurosurg Psychiatry 1988; 51: 10371044.
95. Erickson, R, Howieson, D. et al. The clinician’s perspective: measuring change and treatment effectiveness. In: L. Poon, ed. Clinical Memory Assessment of Older Adults American Psychological Association: Washington, DC. 1986; 6980.
96. Appell, J, Kertesz, A, Fisman, M. A study of language functioning in Alzheimer’s patients. Brain Lang 1982; 17: 7391.
97. Lippa, CF, Johnson, R, Smith, TW. The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer’s disease. Ann Neurol 1998; 43: (1) 102106.
98. McCartney, JR., Physician’s assessment of cognitive capacity:failure to meet the needs of the elderly. Arch Int Med 1986; 146: 177178.
99. Sluss, TK, Rabins, P, Gruenberg, EM, Reedman, G. Memory complaints in community residing men. Gerontologist 1980; 20 (20): 201218.
100. Bolla-Wilson, K, Bleeker, M., Memory complaints – dementia or depression?. Gerontologist 1986; 26:142149.
101. Rubin, EH, et al. Very mild senile dementia of the Alzheimer’s type. I. Clinical assessment. Arch Neurol 1989; 46(4): 379382.
102. Fitz, AG, Teri, L. Depression, cognition, and functional ability in patients with Alzheimer’s disease. J Am Geriatr Soc 1994; 42(2):186191.
103. Barberger-Gateau, P, et al. Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. J Am Geriatr Soc 1992; 40(11): 11291134.
104. Huff, FJ, et al. The neurologic examination in patients with probable Alzheimer’s disease. Arch Neurol 1987; 44: 929933.
105. Serby, M, et al. Olfactory identification deficits in relatives of Alzheimer’s disease patients. Biol Psychiatry 1996; 39(5): 375377.
106. Graves, AB, et al. Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E epsilon4 status. Neurology 1999; 53(7): 14801487.
107. Galasko, D, et al. Neurological findings in Alzheimer’s disease and normal aging. Arch Neurol 1990; 47(6): 625627.
108. Franssen, E, et al. Cognition-independent neurologic symptoms in normal aging and probable Alzheimer’s disease. Arch Neurol 1991; 48(2): 148154.
109. Jenkyn, L, Reeves, A, Warner, T et al. Neurological signs in senescence. Arch Neurol 1985; 42: 11541157.
110. Huff, F, Growdon, J., Neurological abnormalities associated with severity of dementia in Alzheimer’s disease. Can J Neurol Sci 1986; 13(4Suppl): 403405.
111. Lopez, OL, et al. Extrapyramidal signs in patients with probable Alzheimer’s disease. Arch Neurol 1997; 54(8): 969969.
112. Folstein, MF, Folstein, SE, McHugh, PR.Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189198.
113. Siu, A. Screening for dementia and investigating its causes (review). Ann Int Med 1991; 115(2): 122132.
114. Tombaugh, TN, McIntyre, NJ. The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc 1992; 40: 922935.
115. Dick, JPR, et al. Mini-Mental State Examination in neurological patients. J Neurology Neurosurg Psychiatry 1984; 47: 496499.
116. Clark, CM, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer’s disease: A clinical perspective of data from the Consortium to Establish a Registry for Alzheimer’s Disease. Arch Neurol 1999; 56(7): 857862.
117. Grober, E, Buschke, HCHBS, Dresner, R. Screening for dementia by memory testing. Neurology 1988; 38(6): 900903.
118. Tuokko, H, et al. The Clock Test: a sensitive measure to differentiate normal elderly from those with Alzheimer’s disease. J Am Geriatr Soc 1992; 40(6): 579584.
119. Stahelin, HB, Monsch, AU, Spiegel, R. Early diagnosis of dementia via a two-step screening and diagnostic procedure. Int Psychogeriatr 1997; 9(Suppl1): 123130.
120. Solomon, PR, et al. A 7 minute neurocognitive screening battery highly sensitive to Alzheimer’s disease. Arch Neurol 1998; 55(3): 349355.
121. Huff, FJ, et al. Cognitive deficits and clinical diagnosis of Alzheimer’s disease. Neurology 1987; 37(7): 11191124.
122. Chui, H, Zhang, Q. Evaluation of dementia: a systematic study of the usefulness of the American Academyof Neurology’s practice parameters. Neurology 1997; 49(4): 925935.
123. Stern, Y, et al. Diagnosis of dementia in a heterogeneous population. Arch Neurol 1992; 49(5): 453460.
124. Clarfield, M., Assessing dementia: the Canadian Consensus. Can Med Assoc J 1991; 144: 851853.
125. Corey-Bloom, J., et al. Diagnosis and evaluation of dementia. Neurology 1995; 2: 211218.
126. Patterson, CJ, et al. Canadian Consensus Conference on Dementia: a physician’s guide to using the recommendations [seecomments]. Can Med Assoc J 1999; 160(12): 17381742.
127. Helkala, EL, et al. Different patterns of cognitive decline related to normal or deteriorating EEG in a 3-year follow-up study of patients with Alzheimer’s disease. Neurology 1991; 41(4): 528532.
128. Hammerstrom, DC, Zimmer, B. The role of lumbar puncture in the evaluation of dementia: the University of Pittsburgh study. J Am Geriatr Soc 1985; 33(4): 397400.
129. Hsich, G, et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies [see comments]. New Eng J Med 1996; 335(13): 924930.
130. (AAN)Quality Standards Subcommittee of the Americal Academy of Neurology. Practice parameter for diagnosis and evaluation of dementia (Summary statement). Neurology 1994; 44: 22032206.
131. Rossor, MN. Management of neurological disorders: dementia. Neurol Neurosurg Psychiatry 1994; 57: 14511456.
132. Small, GW et al. Diagnosis and treatment of Alzheimer's disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association and the AmericanGeriatrics Society. JAMA 1997; 278(16): 13631371.
133. Gordon, M, Freedman, M. Evaluating dementia: What price testing?. Can Med Assoc J 1990; 142(12): 13671370.
134. Gauthier, S. Costs of diagnostic procedures. In: Wimo A, Jonsson B, Karlsson G, Winblad B, eds. Health Economics of Dementia. Chichester: John Wileyand Sons 1998; 269275.
135. Patterson, C, Gauthier, S, Bergman, H, et al. The recognition, assessment and management of dementingdisorders: conclusions from the Canadian Consensus Conference on Dementia. Can Med Assoc J. 1999; 160(suppl12): S1–S15.
136. Creasey, H et al. Quantitative computed tomography in dementia of the Alzheimer’s type. Neurology. 1986; 36(12): 15631568.
137. Freter, S, et al. Prevalence of potentially reversible dementias and actual reversibility in a memory clinic cohort. Can Med Assoc J. 1998; 159(6): 657662.
138. Willmer, J, et al. The usefulness of CT scanning in diagnosing dementia of the Alzheimer’s type. Can J Neurol Sci. 1993; 20(3):210216.
139. de Leon, MJ, et al. The radiologic prediction of Alzheimer’s disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol. 1993; 14(4):897906.
140. Kidron, D, et al. Quantitative MR volumetry in Alzheimer’s disease. Topographic markersand the effects of sex and education. Neurology 1997; 49(6):15041512.
141. Jack, C, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999; 52(7):13971403.
142. Murtha, S, et al. Mild cognitive impairment and the neuroanatomical changes associated with assessment of progression to dementia. Neurobiol Aging. 2000; 21(Suppl1): S29.
143. Steingart, A, et al. Thesignificance of white matter lucencies on CT scan in relation to cognitive impairment. Can J Neurol Sci. 1986; 13(4Suppl): 383384.
144. Steingart, A, et al. Cognitive and neurologic findings in demented patients with diffuse white matter lucencies on computed tomographic scan (leuko-araiosis). Arch Neurol. 1987; 44(1): 3639.
145. Inzitari, D Age-related white matter changes and cognitive impairment [editorial; comment]. Ann Neurol. 2000; 47(2): 141143.
146. Jagust, WJ, Budinger, TF, Reed, BR The diagnosis of dementia with single photon emission computed tomography. Arch Neurol. 1987; 44(3): 258262.
147. Johnson, KA, et al. Preclinical prediction of Alzheimer’s disease using SPECT. Neurology. 1998; 50: 15631571.
148. Powers, WJ, et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer’s disease. Neurology. 1992; 42: 765770.
149. Bergman, H, et al. HM-PAO (CERETEC) SPECTbrain scanning in the diagnosis of Alzheimer’s disease. J Am Geriatr Soc. 1997; 45(1):1520.
150. Jagust, W, et al. Single-photon emission computed tomographic perfusion imaging in autopsy-diagnosed dementia. J Neuroimaging. 1993; 3: 9399.
151. Geaney, D, Abouh-saleh, M. The use and applications of singlephoton emission computerised in tomography dementia. Br J Psychiatry. 1990; 157(Suppl9): 6675.
152. Johnson, KA, Holman, L, Rosen, TJ Iofetamine, I 123 single photon emission computed tomography is accurate in the diagnosisof Alzheimer’s disease. Arch Int Med. 1990; 150: 752756.
153. Black, SE., Holman, L, Can SPECT predict the future for mild cognitive impairment?. Can J Neurol Sci. 1999; 26: 46.
153a. Johnson, KA, Jones, K, Holman, BL, et al. Preclinical prediction of Alzheimer’s disease using SPECT. Neurology. 1998; 50: 15631571.
154. McKelvey, R, et al. Lackof prognostic significance of SPECT abnormalities in non-demented elderly subjects with memoryloss. Can J Neurol Sci. 1999; 26: 2328.
155. Kennard, M. Diagnostic markers for A lzheimer’s disease. Neurobiol Aging. 1998; 19(2): 131132.
155a. Galasko, D. CSF tau and AB42: logical biomarkers for Alzheimer’s disease. Neurobiol Aging. 1998; 19(2): 117119.
156. Schipper, HM, Chertkow, H, Mehindate, K, et al. Evaluation of heme oxygenase-1 levels as a systemic biological marker of sporadic AD. Neurology. 2000; 54: 12971304.
157. Mayeux, R, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease. New Eng J Med. 1998; 338(8): 506511.
158. Corder, EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late-onset families. Science. 1993; 261(5123): 921923.
159. Farlow, MR. Alzheimer’s disease: clinical implications of the apolipoprotein E genotype. Neurology. 1997; 48(Suppl6): S30–S34.

Assessment of Suspected Dementia

  • H. Chertkow (a1) (a2) (a3) (a4), H. Bergman (a1) (a2), H.M. Schipper (a1) (a2), A.M. Clarfield (a5), S. Gauthier (a4), S. Fontaine (a6) and R. Bouchard (a7)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed